Neoadjuvant chemotherapy for resectable esophageal carcinoma: A meta-analysis of randomized clinical trials

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 103-110

  Xu, Xiao Hua ^a,b   Peng, Xue Hong ^c   Yu, Ping ^a   Xu, Xiao Yuan ^a   Cai, Er Hui ^a   Guo, Pi ^a   Li, Ke ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b First Republic Hospital of JingDeZhen   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Esophageal neoplasms; Meta analysis; Neoadjuvant chemotherapy; Randomized controlled trial; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; HUMAN; META ANALYSIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84864886964     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.103     Document Type: Article

References (45)

1. AAllum WH, Stenning SP, Bancewicz J, et al (2009). Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 27, 5062-7.
2. Ancona E, Ruol A, Santi S, et al (2001). Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer, 91, 2165-74.
3. Ando N, Ozawa S, Kitagawa Y, et al (2000). Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg, 232, 225-32.
4. Baba M, Natsugoe S, Shimada M, et al (2000). Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus, 13, 136-41.
5. Bokhyan V, Stilidi I, Malikhova O, et al (2009). Neoadjuvant chemotherapy followed by transthoracic resection for locally advanced carcinoma of the esophagus: a randomized study. European Journal of Cancer Supplements, 7, 377.
6. Bollschweiler E, Wolfgarten E, Gutschow C, et al (2001). Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer, 92, 549-55.
7. Cao XF, Wu BC, Wang S, et al (2001). A study of esophageal cancer systemic therapy mode with surgery as the main treatment. Chinese J Clinic Oncol Rehabilitation, 8, 25-6.
8. Crew KD, Neugut AI, (2004). Epidemiology of upper gastrointestinal malignancies. Semin Oncol, 31, 450-64.
9. Cunningham D, Allum WH, Stenning SP, et al (2001). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20.
10. Eslick GD (2009). Epidemiology of esophageal cancer. Gastroenterol Clin North Am, 38, 17-25
11. Gebski V, Burmeister B, Smithers BM, et al (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 8, 226-34.
12. Greil R, Stein HJ (2007). Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol, 8, 189-90.
13. Higgins JPT, Green S, editors (2009). Assessing risk of bias in included studies: Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009], The Cochrane Collaboration, Available from www.cochrane-handbook.org.
14. Igaki H, Koto H, Ando N, et al (2008). A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/?squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol, 26, S4510.
15. Iyer R, Wilkinson N, Demmy T, et al (2004). Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined- modality therapy. Ann Surg Oncol, 11, 665-73.
16. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
17. Kaklamanos IG, Walker GR, Ferry K, et al (2003). Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol, 10, 754-61.
18. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.
19. Katlic MR, Wilkins EJ, Grillo HC (1997). Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg, 99, 929-38.
20. Kelsen D (1997). Multimodality therapy for adenocarcinoma of the esophagus. Gastroenterol Clin North Am, 26, 635-45.
21. Kelsen DP, Ginsberg R, Pajak TF, et al (1998). Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med, 339, 1979-84.
22. Kelsen DP, Winter KA, Gunderson LL, et al (2007). Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol, 25, 3719-25.
23. Khushalani N (2008). Cancer of the esophagus and stomach. Mayo Clin Proc, 83, 712-22.
24. Law S, Fok M, Chow S, et al (1997). Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg, 114, 210-7.
25. Liao QM, Wang XY, Yi NT, et al (1993). Preoperative chemotherapy for esophageal carcinoma in contrast with single surgery on local lymph nodes metastasis and curative effect. Henan J Oncol 6, 34-6.
26. Ma BQ, Zhang YF, Guo HZ (2007). Neoadjuvant chemotherapy for stage III esophageal squamous cell carcinoma. China J Modern Med, 17, 2244-6.
27. Maipang T, Vasinanukorn P, Petpichetchian C, et al (1994). Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol, 56, 191-7.
28. Malthaner R, Fenlon D (2003). Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev, 4, CD001556.
29. Medical Research Council Oesophageal Cancer Working Group (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet, 359, 1727-33.
30. Meyenberger C, Fantin AC (2000). Esophageal carcinoma: current staging strategies. Recent Results Cancer Res, 155, 63-72.
31. Millar J, Scullin P, Morrison A, et al (2005). Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer, 93, 1112-6.
32. Nygaard K, Hagen S, Hansen HS, et al (1992). Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg, 16, 1104-10.
33. Orringer MB, Marshall B, Iannettoni MD (1999). Transhiatal esophagectomy: clinical experience and refinements. Ann Surg, 230, 392-403.
34. Parkin DM, Muir CS, (1992). Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ, 1992, 45-173.
35. Peng Y, Du YB, Ma YF (2007). Clinical analysis of preoperative new adjuvant chemotherapy in local advanced esophageal carcinoma. Chinese J Practice Med, 6, 780-1.
36. Pohl H, Welch HG (2005). The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst, 97, 142-6.
37. Roth JA, Pass HI, Flanagan MM, et al (1998). Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg, 96, 242-8.
38. Schlag PM (1992). Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg, 127, 1446-50.
39. Shah MA, Kelsen DP (2004). Combined modality therapy of esophageal cancer: changes in the standard of care? Ann Surg Oncol, 11, 641-3.
40. Sutton P, Clark P (2000). Neo-adjuvant treatment for oesophageal cancer. GI Cancer, 3, 231-8.
41. Urschel JD, Vasan H, Blewett CJ (2002). A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg, 183, 274-9.
42. van Meerten E, Eskens FA, van Gameren EC, et al (2007). First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer, 96, 1348-52.
43. Wang CL, Ding T, Chang LB, et al (2001). A randomized clinical study of preoperative chemotherapy for esophageal carcinoma. Chin J Oncol, 23, 254-5.
44. Whooley BP, Law S, Murthy SC, et al (2001). Analysis of reduced death and complication rates after esophageal resection. Ann Surg, 233, 338-44.
45. Zhu K, Li K, Dang CX, et al (2008). Effect of neo-adjuvant chemotherapy (BPF regimen) on the expression of MVD and VEGF in esophageal carcinoma. China Cancer, 17, 518-20